A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-Resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- May 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Research Site · Miami, FL
- Research Site · Tampa, FL
Illinois · 1
- Research Site · Chicago, IL
Massachusetts · 1
- Research Site · Boston, MA
Nebraska · 1
- Research Site · Omaha, NE
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.